维普期刊资源整合服务平台（V6.5）

164篇 您的检索式：作者名="Burris HA 3rd"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	Carcinoma ofunknown primary site显示文摘	Greco FA Burris HA 3rd Erland JB	2000	Cancer2000，89，12：	1
2	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial 显示文摘	Burris HA 3rd Moore M J Andersen J	1997	J Clin Oncol1997，15，6：	1
3	Improve- ments in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial显示文摘	Burris HA 3rd Moore M J Andersen J	1997	J Clin Oncol1997，15，6：	1
4	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial 显示文摘	Burris HA 3rd Moore MJ Andersen J	1997	J Clin Oncol1997，15，6：	1
5	Weekly doeetaxel in the treatment of elderly patients with advanced breast cancer 显示文摘	Hainsworth JD Burris HA 3rd Yardley DA	2001	J Clin Oncol2001，19，15：	1
6	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:A randomized trial显示文摘	Burris HA 3rd Moore MJ Andersen J	1997	J Clin Oncol1997，15，6：	1
7	A phase lI trial of gemcitabine/carboplatin with or without trastuzumab in the first- line treatment of patients with metastatic breast cancer显示文摘	Yardley DA Burris HA 3rd Simons L	2008	Clin Breast Cancer2008，8，5：	1
8	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial显示文摘	Burris HA 3rd Moore MJ Andersen J	1997	J Clin Oncol1997，15，6：	1
9	Phase II Trial of Bevacizumab and everolimus in patients with advanced renal cell carcinoma 显示文摘	Hainsworth JD Spigel DR Burris HA 3rd	2010	J Clin Oncol2010，，：	1
10	Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase Ⅱ trial 显示文摘	Hainsworth JD Burris HA 3rd Yardley DA	2001	J Clin Oncol2001，19，15：	1
11	Phase II study of the an- tibody drug conjugate trastuzumab- DM1 for the treatment of hu- man epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2--directed therapy显示文摘	Burris HA 3rd Rugo HS Vukelja SJ	2011	J Clin Oncol2011，29，4：	1
12	Improvements in survival and clinical Benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial 显示文摘	Burris HA 3rd Moore MJ Andersen J	1997	J Clin Oncol1997，15，：	1
13	Improvements in survival and clinical benefit with gemcitabine as first - line therapy for patients with advanced pancreas cancer : a randomized trial显示文摘	Burris HA 3rd Moore M J Andersen J	1997	J Clin Oncol1997，15，6：	1
14	Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial 显示文摘	Burris 3rd HA Moore M J Andersen J	1997	J Clin Oncol1997，15，13：	1
15	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial显示文摘	Burris HA 3rd Moore MJ Andersen J	1997	JClin Oncol1997，15，6：	1
16	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial显示文摘	Burris HA 3rd Moore M J Andersen J	1997	J Clin Oncol1997，15，6：	1
17	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial显示文摘	Burris HA 3rd Moore MJ Andersen J		0，，：	1
18	Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial显示文摘	Burris HA 3rd Moore MJ Andersen J	1997	J Clin Oncol1997，15，6：	1
19	Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinb(GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas显示文摘	Burris HA 3rd Hurwiz HI Dees EC	2005	J Clin Oncol2005，23，：	1
20	Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib(GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas显示文摘	Burris HA 3rd Hurwitz HI Dees EC	2005	J Clin Oncol2005，23，23：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示